Exercise attenuates pulmonary injury in mice with bleomycin-induced pulmonary fibrosis.
Human idiopathic pulmonary fibrosis (IPF) is a disease with unknown etiology and poor prognosis in which patients present a decrease in functional exercise tolerance and quality of life. At present, no treatment which can improve the prognosis of this disease is available. Many biomarkers of pulmonary fibrosis have been studied, and surfactant protein A (SP-A) expression is considered a specific marker of lung disease. This study aimed to investigate the influence of exercise training on exercise endurance capacity and murine-lung lesions induced by bleomycin (BLM). Thirty-four male Balb/c mice were subdivided into four groups: control sedentary (C-SED), bleomycin-treated sedentary (BLM-SED), control exercised (C-EXE) and bleomycin-treated exercised (BLM-EXE). Mice received 6.25 U/kg of BLM or saline via intratracheal instillation. After adaptation in a swimming pool, the animals started training one hour per day, with 60% of maximum load obtained in exercise endurance capacity assessment, five days/week for four weeks. The lungs were collected 48 h after the second endurance capacity assessment, fixed in buffered formalin and embedded in paraffin. Sections were analyzed using histochemical and immunohistochemical reactions for digital morphometry of pulmonary fibrosis, type I collagen, SP-A and type II pneumocytes (PII). The exercise endurance capacity of groups C-EXE (9.20 ± 0.81 min) and BLM-EXE (8.40 ± 0.82 min) increased significantly when compared with groups C-SED (5.84 ± 0.4 min) and BLM-SED (5.67 ± 0.60 min). The amounts of connective tissue, type I collagen, PII and SP-A increased significantly in the BLM-SED group. Exercise training significantly attenuated this response as observed in the BLM-EXE group. The present study shows that exercise training can prevent the decline of exercise endurance capacity and attenuate the progression of IPF.
Programa de Pós-Graduação em Patologia, Instituto de Ciê ncias Biológicas da Universidade Federal de Minas Gerais, Minas Gerais, Brazil.
Luana O
LO
Prata
Fabrício M S
FM
Oliveira
Tatiana M S
TM
Ribeiro
Pedro W M
PW
Almeida
Jefferson A
JA
Cardoso
Maria da Glória
Mda G
Rodrigues-Machado
Marcelo V
MV
Caliari
D056809:Alveolar Epithelial Cells / Q000166:cytology; D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage / Q000633:toxicity*; D024042:Collagen Type I / Q000032:analysis; D006651:Histocytochemistry; D007150:Immunohistochemistry; D007322:Instillation, Drug; D008168:Lung / Q000473:pathology; D055370:Lung Injury / Q000139:chemically induced* / Q000150:complications*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010805:Physical Conditioning, Animal; D011658:Pulmonary Fibrosis / Q000473:pathology* / Q000517:prevention & control*; D037662:Pulmonary Surfactant-Associated Protein A / Q000032:analysis; D014132:Trachea
D024042:Collagen Type I; D037662:Pulmonary Surfactant-Associated Protein A; D001761:Bleomycin